Observational Analysis of Antineoplastic and Immunomodulating Drug Expenditure in Two Local Health Units in Northern Italy during the Period 2009-2011

Analisi osservazionale della spesa per farmaci antineoplastici e immunomodulatori a carico di due ASL del Nord Italia durante il triennio 2009-2011

  • Carlo Cerra U.O.C. Sistema Informativo e Controllo di Gestione, ASL della provincia di Pavia, Pavia - Italy
  • Mirosa Dellagiovanna Dipartimento Governo della Rete Distrettuale e del Farmaco, ASL della provincia di Pavia, Pavia - Italy
  • Simona Migliazza U.O.C. Sistema Informativo e Controllo di Gestione, ASL della provincia di Pavia, Pavia - Italy
  • Roberto Tettamanti U.O.C. Osservatorio Epidemiologico e Sistemi Informativi, ASL della provincia di Como, Como - Italy
  • Corrado Zuliani U.O.C. Servizio Assistenza Farmaceutica, ASL della provincia di Como, Como - Italy
  • Roberto Ravasio Health Publishing & Services Srl, Milano - Italy
  • Delia Colombo Patient Access Novartis Farma Italia, Novartis Farma S.p.A., Origgio (VA) - Italy
  • Claudia Pitotti Patient Access Novartis Farma Italia, Novartis Farma S.p.A., Origgio (VA) - Italy
  • Emanuela Zagni Patient Access Novartis Farma Italia, Novartis Farma S.p.A., Origgio (VA) - Italy
Keywords: Antineoplastic and immunomodulating drugs, Drug expenditure, Italian Local Health Unit, Therapeutic indication

Abstract

Background The past few years, the Italian National Health Service (INHS) has faced the challenge of ensuring sustainable costs for antineoplastic and immunomodulating drugs. The aim of this study was to analyse expenditure trends for these drugs in two Local Health Units during the period 2009-2011. Methods Data for this retrospective study were derived from the administrative databases of two Local Health Units in Northern Italy. A sample was built up by selecting all patients with at least one antineoplastic and immunomodulating drug prescription between 2009 and 2011. The study evaluated the annual, per capita and per user drug expenditure. The antineoplastic and immunomodulating drug expenditure was also analysed by therapeutic indication. Results The number of users (annual mean rate: 12.1%) and the antineoplastic and immunomodulating drug expenditure (annual mean rate: 15.7%) were increased in the three-year period. The mean annual per capita cost was €18.40 in the first year (2009), €22.18 in the second year (2010) and €24.23 in the last year (2011). Taking into account the last year of the analysis (2011), monoclonal antibody drugs showed the highest per capita drug spending (€9.36), followed by TNF-alpha inhibitors (€6.61) and tyrosine kinase inhibitors (€5.75). The highest mean annual expenditure was on cancer drugs (€15,046,773), followed by rheumatoid arthritis (€3,596,925), psoriatic arthritis (€925,510), ankylosing spondylitis (€626,050) and psoriasis (€622,332). Conclusions Spending on antineoplastic and immunomodulating drugs increased over the three-year period of the analysis and the oncological disease was the main therapeutic indication.
Published
2016-10-18
How to Cite
CerraC., DellagiovannaM., MigliazzaS., TettamantiR., ZulianiC., RavasioR., ColomboD., PitottiC., & ZagniE. (2016). Observational Analysis of Antineoplastic and Immunomodulating Drug Expenditure in Two Local Health Units in Northern Italy during the Period 2009-2011. Global & Regional Health Technology Assessment, 3(3), 134-143. https://doi.org/10.33393/grhta.2016.361
Section
Original Research Article

Most read articles by the same author(s)